Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond
The DOI matches its Crossref record; 9 of the 10 references it cites were found in a registry or an index.
Abstract
Summary: Hallin and colleagues demonstrate the preclinical activity of the KRASG12C-specific inhibitor MRTX849 in a series of in vitro and in vivo studies with supporting pilot clinical efficacy. Variable responsiveness despite effective KRASG12C inhibition highlights both the promise and potential need for combinatorial strategies to optimally target KRASG12C-driven cancers. See related article by Hallin et al., p. 54.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2019, phase I/II clinical trials of both AMG-510 and MRTX849 demonstrated safety and therapeutic activity, notably in non-small cell lung cancer (NSCLC), where the frequency of KRASG12C mutation approaches 15% (Table 2).6,50,51”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [51]
In the citing paper
“Although early-phase clinical trial results among NSCLC patients are promising, responses from colorectal cancer patients treated with either AMG-510 or MRTX849 were far less impressive, which raises the question of whether the overall efficacy of K-RasG12C inhibitors might be cancer type dependent.51”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [51]
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30027-0 · Cited by 577 · cited 1×
“It is worth noting that early excitement over increased T-cell infiltration in response to a somewhat analogous combination of MEK and anti–PD-L1 inhibitors in KRAS-mutant microsatellite-stable colorectal cancers did not ultimately translate into improved patient outcomes, although the tumor-selective activity of KRAS…”
BackgroundParikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G., Livitz, D., Rhrissorrakrai, K., Martin, E. E., Van Seventer, E. E., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0561-9 · Cited by 518 · cited 1×
“Will we observe alterations or activation of pathways shown to mediate intrinsic resistance such as RTK signaling, or will other mechanisms emerge? Will additional RAS mutations, which are commonly observed in colorectal cancers treated with EGFR antibodies but rarely seen in NSCLC treated with EGFR or ALK inhibitors,…”
BackgroundTherapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259
Self-citationKRAS G12C inhibition produces a driver-limited state revealing collateral dependencies
Lou, K., Steri, V., Ge, A. Y., Hwang, Y. C., Yogodzinski, C. H., Shkedi, A. R., Choi, A. L. M., Mitchell, D. C., Swaney, D. L., Hann, B., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw9450 · Cited by 175
Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours
Govindan, R., Fakih, M. G., Price, T. J., Falchook, G. S., Desai, J., Kuo, J. C., Strickler, J. H., Krauss, J. C., Li, B. T., Denlinger, C. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz244.008 · Cited by 40
Cited by
Immune modulatory effects of oncogenic KRAS in cancer
Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R. (2020) · Nature Communications · doi:10.1038/s41467-020-19288-6 · Cited by 387
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
Mechanisms of Resistance to KRASG12C Inhibitors
Dunnett-Kane, V., Nicola, P., Blackhall, F., & Lindsay, C. (2021) · Cancers · doi:10.3390/cancers13010151 · Cited by 117
Kerr, D. L., Haderk, F., & Bivona, T. G. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.11.007 · Cited by 124
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61
Metadata
- Authors
- Klempner, S. J., & Hata, A. N.
- Affiliations
- Harvard University (US)
- Venue
- Cancer Discovery
- Published
- 2020-01-01
- Volume
- 10
- Issue
- 1
- Pages
- 20-22
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2999411977
- Cited by
- 15
- References
- 10
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 6 · 2020: 4
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- KRAS G12C, KRAS inhibitors, adagrasib, KRAS-driven cancers, combination therapy, drug resistance, targeted cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Disease Models, Animal, Humans, Mutation, Proto-Oncogene Proteins p21(ras), Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.